Key result
Ticagrelor reduced cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in NSTE-ACS patients with hs-TnT ≥14.0 ng/L, but no apparent benefit was seen at normal hs-TnT.
Why the study?
Does ticagrelor compared to clopidogrel reduce cardiovascular death, myocardial infarction, and stroke in patients with NSTE-ACS stratified by biomarker levels (hs-TnT, NT-proBNP, GDF-15)?
RCT (n=9,946)
randomized
Does ticagrelor compared to clopidogrel reduce cardiovascular death, myocardial infarction, and stroke in patients with NSTE-ACS stratified by biomarker levels (hs-TnT, NT-proBNP, GDF-15)?
Elevated hs-TnT identifies NSTE-ACS patients who derive substantial benefit from ticagrelor over clopidogrel, regardless of whether they are managed invasively or noninvasively.
No takes yet. Share an insight, caveat, or question.
Elevated hs-TnT identifies NSTE-ACS patients for ticagrelor over clopidogrel; extends evidence across invasive and noninvasive strategies.
Wallentin et al. (2013) conducted an RCT in non-ST-elevation acute coronary syndrome (NSTE-ACS) (n=9,946). Ticagrelor vs. Clopidogrel was evaluated on cardiovascular death, myocardial infarction, and stroke. Ticagrelor reduced cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in NSTE-ACS patients with hs-TnT ≥14.0 ng/L, but no apparent benefit was seen at normal hs-TnT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: